Cidecin Manufacturing Issues Could Delay Launch By “A Number Of Weeks”
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Manufacturing issues are likely to delay the launch of Cubist’s cyclic lipopeptide antibiotic Cidecin by “a number of weeks” after the anticipated Sept. 20 approval, the firm said.